2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on HER2+ NSCLC: Did Trastuzumab Deruxtecan Demonstrate Favorable Clinical Activity?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Shayma Kazmi
By 2020 ASCO Virtual Direct™ Highlights FEATURING Shayma Kazmi
0 views
September 22, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

17:33
AstraZeneca Oncology

First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…

Feat. S. Lewin
Lung
24:44
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on EGFR+ NSCLC: Adjuvant Gefitinib, Adjuvant Osimer…

Feat. S. Kazmi
09:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in Advanced NSCLC: Nivo/Ipi + 2 Cycles of Che…

Feat. S. Kazmi
08:01
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ NSCLC: Did Trastuzumab Deruxtecan Demonstr…

Feat. S. Kazmi
08:01
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on SCLC: Can a Higher TRT-Dose Prolong Survival…

Feat. S. Patel
07:39
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Localized NSCLC: Does the Addition of Pembro…

Feat. S. Patel
06:39
2020 ASCO Virtual Direct™ Highlights

Adjuvant Therapy in Resectable NSCLC: What Does ADAURA Data Suggest …

Feat. S. Patel